Association of sex hormones, aging, and atrial fibrillation in men the framingham heart study

Circulation: Arrhythmia and Electrophysiology

Volumn 7, Issue 2, 2014, Pages 307-312

  Magnani, Jared W ^a,b   Moser, Carlee B ^d   Murabito, Joanne M ^a,c   Sullivan, Lisa M ^d   Wang, Na ^d   Ellinor, Patrick T ^e,f   Vasan, Ramachandran S ^a,b   Benjamin, Emelia J ^a,b   Coviello, Andrea D ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sect of Gen Int Medicine (111 0)   (United States)

^d Department of Medicine   (United States)

^e Cardiovascular Research Center   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aging; Atrial fibrillation; Epidemiology; Men

Indexed keywords

ESTRADIOL; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; AGE; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

AGING; ATRIAL FIBRILLATION; EPIDEMIOLOGY; MEN;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84900407645     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.001322     Document Type: Article

References (43)

1. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107:85-91.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
3. Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB Sr, Bhasin S, Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145:176-184.
4. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1557-1564.
5. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, Schöfl C, Dörr M, Nauck M, Wallaschofski H. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010;31:1494-1501.
6. Lehtonen A, Huupponen R, Tuomilehto J, Lavonius S, Arve S, Isoaho H, Huhtaniemi I, Tilvis R. Serum testosterone but not leptin predicts mortality in elderly men. Age Ageing. 2008;37:461-464.
7. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Ling SM, Metter EJ, Artoni A, Carassale L, Cazzato A, Ceresini G, Guralnik JM, Basaria S, Valenti G, Ferrucci L. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007;167:2249-2254.
8. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab. 2009;94:2482-2488.
9. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979;110:281-290.
10. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, Kannel WB, Wang TJ, Ellinor PT, Wolf PA, Vasan RS, Benjamin EJ. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739-745.
11. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000;133:951-963.
12. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
13. Lai J, Zhou D, Xia S, Shang Y, Want L, Zheng L, Zhu J. Reduced testosterone levels in males with lone atrial fibrillation. Clin Cardiol. 2009;32:43-46.
14. Eby G. Testosterone as an atrial fibrillation treatment and stroke preventative in aging men: case histories and hypothesis. Med Hypotheses. 2010;75:269-270.
15. Abbott RD, Launer LJ, Rodriguez BL, Ross GW, Wilson PW, Masaki KH, Strozyk D, Curb JD, Yano K, Popper JS, Petrovitch H. Serum estradiol and risk of stroke in elderly men. Neurology. 2007;68:563-568.
16. Vandenplas G, De Bacquer D, Calders P, Fiers T, Kaufman JM, Ouwens DM, Ruige JB. Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies. Heart. 2012;98:1478-1482.
17. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288-1299.
18. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207:318-327.
19. Messerli FH, Garavaglia GE, Schmieder RE, Sundgaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107:158-161.
20. Svartberg J, von Mühlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur J Endocrinol. 2004;150:65-71.
21. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929-931.
22. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159:850-856.
23. Magnani JW, Lopez FL, Soliman EZ, Maclehose RF, Crow RS, Alonso A. P wave indices, obesity, and the metabolic syndrome: the atherosclerosis risk in communities study. Obesity (Silver Spring). 2012;20:666-672.
24. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-2477.
25. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2006;65:125-131.
26. Cao J, Chen TM, Hao WJ, Li J, Liu L, Zhu BP, Li XY. Correlation between sex hormone levels and obesity in the elderly male. Aging Male. 2012;15:85-89.
27. Garcia-Cruz E, Piqueras M, Huguet J, Perez-Marquez M, Gosalbez D, Peri L, Izquierdo L, Luque P, Ribal MJ, Alcaraz A. Hypertension, dyslipidemia and overweight are related to lower testosterone levels in a cohort of men undergoing prostate biopsy. Int J Impot Res. 2012;24:110-113.
28. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90:712-719.
29. Lam CS, Cheng S, Choong K, Larson MG, Murabito JM, Newton-Cheh C, Bhasin S, McCabe EL, Miller KK, Redfield MM, Vasan RS, Coviello AD, Wang TJ. Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol. 2011;58:618-626.
30. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, Keaney JF Jr, Wang TJ, Vasan RS, Benjamin EJ. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol. 2009;104:92-96.
31. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768-1774.
32. Tsuneda T, Yamashita T, Kato T, Sekiguchi A, Sagara K, Sawada H, Aizawa T, Fu LT, Fujiki A, Inoue H. Deficiency of testosterone associates with the substrate of atrial fibrillation in the rat model. J Cardiovasc Electrophysiol. 2009;20:1055-1060.
33. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, Sparks PB, Kalman JM. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44:109-116.
34. Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259:576-582.
35. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves highdensity lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427-2434.
36. Li S, Li X, Li Y. Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol. 2008;49:14-18.
37. Güder G, Frantz S, Bauersachs J, Allolio B, Ertl G, Angermann CE, Störk S. Low circulating androgens and mortality risk in heart failure. Heart. 2010;96:504-509.
38. Jankowska EA, Rozentryt P, Ponikowska B, Hartmann O, Kustrzycka- Kratochwil D, Reczuch K, Nowak J, Borodulin-Nadzieja L, Polonski L, Banasiak W, Poole-Wilson PA, Anker SD, Ponikowski P. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301:1892-1901.
39. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829-1837.
40. Naghi JJ, Philip KJ, DiLibero D, Willix R, Schwarz ER. Testosterone therapy: treatment of metabolic disturbances in heart failure. J Cardiovasc Pharmacol Ther. 2011;16:14-23.
41. Iellamo F, Rosano G, Volterrani M. Testosterone deficiency and exercise intolerance in heart failure: treatment implications. Curr Heart Fail Rep. 2010;7:59-65.
42. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013;98:4300-4310.
43. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.